Thermo Fisher Scientific Expands its Global Biologics and Steriles Manufacturing Capabilities in China
As the global biologics market and scientific advancements in biopharmaceuticals continues to rise, so has the demand for therapeutics, expanding indications for biologics, and the growing portfolios of biosimilars. This growth is good news for patients and makers of therapies alike—however, growth always comes with new challenges.
In this case, the industry must learn how to deploy efficient, flexible manufacturing technologies that can respond to many variables. These variables include the proliferation of new biologics, rapid shifts in annual volumetric requirements, and improvements in cell culture strategies. A new generation of single-use bioreactors, built to deliver high-volume performance, can address and curb these new challenges. Download this whitepaper to learn more.